The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy

Basit Öğe Kaydı
dc.authoridGUR, FATIH MEHMET/0000-0001-7748-3272
dc.authoridAKTAS, IBRAHIM/0000-0002-0956-8204
dc.contributor.authorGur, Fatih Mehmet
dc.contributor.authorAktas, Ibrahim
dc.date.accessioned2024-11-07T13:31:36Z
dc.date.available2024-11-07T13:31:36Z
dc.date.issued2021
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractDiabetic cardiomyopathy (DCM) is a cardiac dysfunction observed in a patient with diabetes that may lead to heart failure. No specific treatment has yet been tested in DCM. Therefore, in this study, it was investigated that the potential of thymoquinone (TYM) and beta-aminoisobutyric acid (BAIBA) to treat DCM. Five groups (n = 7) were formed, namely control, diabetes, TYM, BAIBA and TYM + BAIBA, with a random selection from 35 adult male rats. Diabetes mellitus was induced by intraperitoneal administration of 50 mg/kg streptozotocin to all groups except the control. After establishing experimental diabetes, TYM (20 mg/kg/day) and BAIBA (100 mg/kg/day) were administered alone or in combination with other groups other than the control and diabetes groups for five weeks by gavage. Serum aspartate aminotransferase, lactate dehydrogenase, creatine kinase-MB, and tissue malondialdehyde levels increased significantly, and tissue glutathione levels decreased in the diabetes group compared to the control group. An increase in the expression of tumor necrosis factor-alpha in the myocardium and the rate of fibrosis and apoptosis were found in the histopathological analysis. In the TYM and BAIBA groups, all pathological changes observed in the diabetes group improved significantly. The therapeutic effects of these agents on DCM are probably due to their antihyperglycemic, antidiabetic, antioxidant, and anti-inflammatory effects. The present results suggested that TYM and BAIBA have the potential therapeutic effects on DCM that were used alone or combined.
dc.description.sponsorshipAdiyaman University Research Foundation [SHMYOMAP/2018-0001]
dc.description.sponsorshipThis study was supported by a grant from Adiyaman University Research Foundation (Project SHMYOMAP/2018-0001).
dc.identifier.doi10.1016/j.tice.2021.101582
dc.identifier.issn0040-8166
dc.identifier.pmid34171519
dc.identifier.scopus2-s2.0-85108346248
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.tice.2021.101582
dc.identifier.urihttps://hdl.handle.net/11480/14944
dc.identifier.volume71
dc.identifier.wosWOS:000681020900028
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherChurchill Livingstone
dc.relation.ispartofTissue & Cell
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241106
dc.subjectBeta-aminoisobutyric acid
dc.subjectDiabetic cardiomyopathy
dc.subjectThymoquinone
dc.subjectStreptozotocin
dc.subjectCK-MB
dc.titleThe ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu